About the Webinar
Interest in cell and gene therapy-based disease prevention and treatment has increased rapidly over the last few decades. However, there are still many hurdles to overcome and further progress to be made in the field. In this presentation, Dr. Elizabeth Louie from Azenta Life Sciences will discuss our innovative cell and gene therapy solutions across the clinical development pipeline. She will highlight Azenta’s adeno-associated virus (AAV) plasmid DNA sequencing (RUO/GLP), preparation, and synthesis solutions for recombinant AAV (rAAV) production, which includes confirmation, maintenance, and correction of inverted terminal repeat (ITR) regions. She will also talk about Azenta’s proprietary Sanger & NGS viral genome sequencing confirmation solutions post-AAV virus packaging, including at the regulatory level, to optimize AAV production for gene therapy development. Finally, Dr. Louie will spotlight Azenta Life Sciences’ robust cold chain infrastructure solutions and expertise, demonstrating how having the appropriate systems and processes in place to maintain strict cold chain-of-custody, while getting the right treatment to the right patient at the right time, addresses this challenge in the industry. A brief overview of biomaterial storage and transport solutions will be capped off with a mention of cold chain products and field service offerings to support research from benchtop to bedside.
